<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04585711</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00105975</org_study_id>
    <secondary_id>1K23AR075874-01A1</secondary_id>
    <nct_id>NCT04585711</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis</brief_title>
  <acronym>PRECISE</acronym>
  <official_title>Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about how adult and children's bodies use&#xD;
      etanercept and how bodyweight influences how well etanercept works. This study will help us&#xD;
      understand the proper dose of etanercept in obese children and adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRECISE is an open-label, single arm, single-center site study to evaluate the&#xD;
      pharmacokinetics (PK) and pharmacodynamics (PD) of dosing interval-optimized etanercept in&#xD;
      obese patients with Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA).&#xD;
      Approximately 30 patients with JIA or RA who are starting etanercept standard-of-care will&#xD;
      take part in the study.&#xD;
&#xD;
      Eligible patients will have blood collections before and after starting the biologic of&#xD;
      interest to assess PK and disease activity. Five (5) blood samples will be collected through&#xD;
      a combination of clinic and home visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2023</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Clearance at steady state as measured by PK sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (V)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Volume of distribution at steady state as measured by PK sampling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median prediction error between observed and model predicted concentrations</measure>
    <time_frame>6 weeks</time_frame>
    <description>We will use PK/PD models to simulate drug concentration for each individual subject. We measure the error between simulated and observed plasma concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change in DAS28/JADAS27</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <description>We will score disease activity using the DAS28 (RA) or JADAS27 (JIA) at baseline and 6 week follow up. We will measure the change in score over 6 weeks.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Optimal dosing</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Obese children (≥ 2 year old) and adults with juvenile idiopathic arthritis (JIA) or Rheumatoid Arthritis (RA) who are starting etanercept as part of their routine medical care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept Optimal dosing</intervention_name>
    <description>Patients will receive Etanercept on an optimal dose interval over a 6-week period based on a PK/PD model.</description>
    <arm_group_label>Optimal dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Diagnosis of Rheumatoid Arthritis (RA) according to the 2010 American College of&#xD;
             Rheumatology Classification Criteria (patients greater than or equal to 16 years of&#xD;
             age at screening)&#xD;
&#xD;
          -  Diagnosis of Juvenile Idiopathic Arthritis (JIA) according to the International League&#xD;
             Against Rheumatism Classification Criteria (children less than 16 years of age at&#xD;
             screening)&#xD;
&#xD;
          -  Initiating treatment with etanercept as standard of care by a patient's primary&#xD;
             rheumatologist&#xD;
&#xD;
          -  Obese at baseline, defined as a body mass index (BMI) greater than or equal to 30&#xD;
             kg/m2 in subjects greater than or equal to 18 years of age, and a BMI greater than or&#xD;
             equal to 95th percentile for age and sex in subjects less than18 years of age&#xD;
&#xD;
          -  Active disease at screening, defined as a DAS28 &gt; 3.2 in adults and JADAS27 &gt; 3.8 in&#xD;
             children&#xD;
&#xD;
          -  Patients using oral corticosteroids (&lt;10 mg) or DMARDs must be on a stable dose for at&#xD;
             least 4 weeks prior to screening&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Receipt of any investigational medical product within the past 12 months&#xD;
&#xD;
          -  Positive urine pregnancy test at screening or planned pregnancy during the study&#xD;
             period&#xD;
&#xD;
          -  Prior exposure to etanercept or any other biologic agent within 5 drug half-lives&#xD;
&#xD;
          -  Contraindication to etanercept (e.g., allergy, current or chronic infection [positive&#xD;
             tuberculosis screening test, positive hepatitis B surface antigen, positive hepatitis&#xD;
             C antibody])&#xD;
&#xD;
          -  Personal history of ever having malignancy, lymphoproliferative disease, or&#xD;
             demyelinating disease&#xD;
&#xD;
          -  Screening safety labs with a hemoglobin of ≤ 9 g/dL, white blood cell count &lt;3.0x109L,&#xD;
             platelets &lt;125,000 x109L, AST/ALT more than 2x the upper limit of normal, or&#xD;
             creatinine &gt; 2 mg/dL for adults and &gt;1 mg/dL for children&#xD;
&#xD;
          -  Evidence of erosive osteoarthritis on plain films (if available at time of screening),&#xD;
             or severe osteoarthritis (defined as any anticipated need for joint replacement within&#xD;
             the next year) as judged by the primary rheumatologist&#xD;
&#xD;
          -  History of any opportunistic infections, or recent severe infection in the 3 months&#xD;
             prior to screening (e.g., hepatitis, pneumonia, pyelonephritis, bacteremia)&#xD;
&#xD;
          -  Heart failure with NYHA classification 3 or more&#xD;
&#xD;
          -  Severe functional impairment status, defined as HAQ &gt;2 and CHAQ &gt;1.75&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Balevic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Balevic Stephen, MD</last_name>
    <phone>919-668-4544</phone>
    <email>Stephen.balevic@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cobbaert Marjan, MPH</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Edna Scarlett</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Etanercept</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

